Myasthenia Gravis: An Updated Review

Myasthenia Gravis (MG) is an autoimmune disease caused by autoantibodies directed at the Neuromuscular Junction (NMJ) causing muscle weakness and fatigability. The disease is further characterized by having either a paraneoplastic form (thymoma-associated) or non-paraneoplastic forms and the disorder is immunologically heterogeneous with different antibodies. Currently available management modalities include symptomatic pharmacological treatment, immunomodulatory drugs, thymectomy and supportive therapies. In this review, we summarize the clinical disorder and highlight the different treatment options available to heath care providers caring for patients with MG.